se of mesenchymal cells for the treatment of patients with respiratory syndrome caused by new coronavirus

Not Applicable

• Conditions: COVID-19-associated acute respiratory distress syndrome; A00-B99

• Registration Number: RBR-3fz9yr
• Lead Sponsor: Paulo Roberto Slud Brofman

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-08-31
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruitment completed
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

COVID-19 patients, that require intensive care surveillance and ventilatory support, PaO2/FiO2 less than or equal to 200 (Berlin criteria of moderate-to-severe acute respiratory)

Exclusion Criteria

Previous or current history of malignancy under treatment; pre-existing thromboembolic disease; concomitant HIV or tuberculosis infection; pre-existing transplant or use immunosuppressive therapy and pregnancy

Study & Design

• Study Type: Intervention
• Study Design: Not specified